SEC 13F Intelligence

Avidity Partners Management LP / ZNTL

Avidity Partners Management LP’s Zentalis Pharmaceuticals Inc Position

Does Avidity Partners Management LP own Zentalis Pharmaceuticals Inc (ZNTL)? Not currently — the last reported position was 2.10M shares worth $42M in Q3 2023; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$42M
Q3 2023
Shares
2.10M
% of Portfolio
+1.70%
Quarters Held
14
position exited

Position History ZNTL

Reported value by quarter
Q2 ’20: $32MQ2 ’20Q3 ’20: $30MQ4 ’20: $59MQ4 ’20Q1 ’21: $55MQ2 ’21: $115MQ2 ’21Q3 ’21: $166MQ4 ’21: $228MQ4 ’21Q1 ’22: $147MQ2 ’22: $101MQ2 ’22Q3 ’22: $91MQ4 ’22: $104MQ4 ’22Q1 ’23: $50MQ2 ’23: $66MQ2 ’23Q3 ’23: $42Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q3 20232.10M$42M+1.70%
Q2 20232.33M$66M+2.30%
Q1 20232.93M$50M+1.67%
Q4 20225.15M$104M+2.25%
Q3 20224.22M$91M+1.86%
Q2 20223.59M$101M+2.31%
Q1 20223.18M$147M+3.05%
Q4 20212.71M$228M+4.84%
Q3 20212.49M$166M+3.68%
Q2 20212.16M$115M+3.11%
Q1 20211.26M$55M+1.51%
Q4 20201.14M$59M+1.91%
Q3 2020904.1K$30M+1.37%
Q2 2020674.5K$32M+2.08%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Avidity Partners Management LP’s full portfolio or all institutional holders of ZNTL.